{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:03:29Z","timestamp":1772892209730,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nucmedbio.2023.108369","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:46:54Z","timestamp":1689997614000},"page":"108369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapy"],"prefix":"10.1016","volume":"122-123","author":[{"given":"Kazuma","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshin","family":"Washiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Munekane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fuchigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Echigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Mishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2023.108369_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0165-6147(92)90030-A","article-title":"A proposal for the classification of sigma binding sites","volume":"13","author":"Quirion","year":"1992","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","article-title":"The molecular function of \u03c3 receptors: past, present, and future","volume":"40","author":"Schmidt","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jphs.2014.07.001","article-title":"Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs","volume":"127","author":"Hayashi","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0020","first-page":"24","article-title":"Overview of sigma-1R subcellular specific biological functions and role in neuroprotection","author":"Lachance","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0025","article-title":"125I-labeled 2-[4-(2-iodophenyl)piperidino]cyclopentanol (125I-OI5V) imaging visualized augmented sigma-1 receptor expression according to the severity of myocardial ischemia","author":"Wakabayashi","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0030","first-page":"408","article-title":"Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines","volume":"55","author":"Vilner","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1158\/0008-5472.CAN-15-1465","article-title":"SIGMAR1 regulates membrane electrical activity in response to extracellular matrix stimulation to drive cancer cell invasiveness","volume":"76","author":"Crott\u00e8s","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0040","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.0c02265","article-title":"Recent advances in the development of sigma receptor ligands as cytotoxic agents: a medicinal chemistry perspective","volume":"64","author":"Fallica","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11307-019-01369-8","article-title":"Imaging sigma-1 receptor (S1R) expression using iodine-124-labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG)","volume":"22","author":"Gangangari","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1039\/D0MD00186D","article-title":"In vitro and in vivo sigma 1 receptor imaging studies in different disease states","volume":"12","author":"Agha","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human sigma1 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41594-018-0137-2","article-title":"Structural basis for sigma1 receptor ligand recognition","volume":"25","author":"Schmidt","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0065","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acsmedchemlett.9b00314","article-title":"Virtual screening for ligand discovery at the sigma1 receptor","volume":"11","author":"Greenfield","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0070","first-page":"22","article-title":"Sigma receptor (sigmaR) ligands with antiproliferative and anticancer activity","author":"Georgiadis","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0075","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1021\/jm980560x","article-title":"Hydroxylated decahydroquinolines as ligands for the vesicular acetylcholine transporter: synthesis and biological evaluation","volume":"42","author":"Efange","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0080","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.bmc.2005.11.044","article-title":"Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor","volume":"14","author":"Shiba","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0085","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bmc.2004.11.029","article-title":"In vitro characterization of radioiodinated (+)-2-[4-(4-iodophenyl) piperidino]cyclohexanol [(+)-pIV] as a sigma-1 receptor ligand","volume":"13","author":"Shiba","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0090","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0024-3205(02)01919-7","article-title":"Characterization of radioiodinated (\u2212)-ortho-iodovesamicol binding in rat brain preparations","volume":"71","author":"Shiba","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.nucmedbio.2007.05.005","article-title":"In vivo characterization of radioiodinated (+)-2-[4-(4-iodophenyl) piperidino] cyclohexanol as a potential sigma-1 receptor imaging agent","volume":"34","author":"Akhter","year":"2007","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0100","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/j.1349-7006.2009.01279.x","article-title":"Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy","volume":"100","author":"Ogawa","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0105","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.bmc.2019.03.054","article-title":"Syntheses and evaluation of a homologous series of aza-vesamicol as improved radioiodine-labeled probes for sigma-1 receptor imaging","volume":"27","author":"Ogawa","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12149-020-01552-w","article-title":"In vitro and in vivo evaluation of [125\/123I]-2-[4-(2-iodophenyl)piperidino]cyclopentanol([125\/123I]-OI5V) as a potential sigma-1 receptor ligand for SPECT","volume":"35","author":"Shigeno","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0115","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1039\/D2MD00099G","article-title":"Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics","volume":"13","author":"Mishiro","year":"2022","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccr.2018.12.005","article-title":"Radiotheranostics with radiolanthanides: design, development strategies, and medical applications","volume":"383","author":"Mishiro","year":"2019","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0125","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1248\/cpb.c19-00274","article-title":"Development of diagnostic and therapeutic probes with controlled pharmacokinetics for use in radiotheranostics","volume":"67","author":"Ogawa","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0130","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1021\/acsomega.8b03679","article-title":"Radiotheranostics coupled between an at-211-labeled RGD peptide and the corresponding radioiodine-labeled RGD peptide","volume":"4","author":"Ogawa","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0135","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.1c00460","article-title":"68Ga- and 211At-labeled RGD peptides for radiotheranostics with multiradionuclides","volume":"18","author":"Ogawa","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0140","first-page":"23","article-title":"Comparison of the therapeutic effects of [211At]NaAt and [131I]NaI in an NIS-expressing thyroid cancer mouse model","author":"Watabe","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0145","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12149-021-01612-9","article-title":"Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0150","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12149-022-01765-1","article-title":"Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)","volume":"36","author":"Ukon","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1248\/cpb.c20-00077","article-title":"Preliminary evaluation of astatine-211-labeled bombesin derivatives for targeted alpha therapy","volume":"68","author":"Aoki","year":"2020","journal-title":"Chem Pharm Bull(Tokyo)"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0160","first-page":"26","article-title":"Development of radiogallium-labeled peptides for platelet-derived growth factor receptor beta (PDGFRbeta) imaging: influence of different linkers","author":"Effendi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/2191-219X-2-54","article-title":"Development and evaluation of a novel radioiodinated vesamicol analog as a sigma receptor imaging agent","volume":"2","author":"Ogawa","year":"2012","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2015.07.001","article-title":"Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy","volume":"42","author":"Ogawa","year":"2015","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0175","first-page":"4578","article-title":"Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors","volume":"59","author":"John","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0180","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.1021\/acs.jmedchem.1c01147","article-title":"Neopentyl glycol as a scaffold to provide radiohalogenated theranostic pairs of high in vivo stability","volume":"64","author":"Suzuki","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2023.108369_bb0185","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:31:27Z","timestamp":1760848287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805123000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":37,"alternative-id":["S0969805123000574"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108369","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapy","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108369"}}